From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Ocrelizumab is a pharmaceutical treatment developed for people with primary-progressive Multiple sclerosis (MS). It is an immunosuppressive drug that targets mature B cell lymphocytes which have the CD20 antibody on their surface. The therapy is similar to rituximab.[1] Ocrelizumab is registered under the brand name Ocrevus, and on May 28, 2017, received approval by the U.S. Food and Drug Administration for treating MS.[2][3]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]